Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Irene Attucci
Observed name:
I. Attucci
Institutions:
Azienda Ospedaliero-Universitaria Careggi,
University of Florence
Observed institutions:
Azienda Ospedaliero-Universitaria Careggi,
University of Florence
ORCID:
0000-0002-7301-5559
Observed ORCID:
0000-0002-7301-5559
OpenAlex ID:
A5022993372
Daratumumab, lenalidomide, and dexamethasone combination in relapsed/refractory myeloma patients: a real-life single-center experience
2020
·
Elisabetta Antonioli
, Michela Staderini
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
13
Carfilzomib plus dexamethasone in patients with relapsed and refractory multiple myeloma: A retro‐prospective observational study
2022
·
Maria Livia Del Giudice
, Alessandro Gozzetti
, et al.
·
European Journal Of Haematology
·
8
PDF
Daratumumab in AL Amyloidosis: A Real-Life Experience of the “RTM” (Regional Tuscan Myeloma Network)
2022
·
Vincenzo Sammartano
, Elisabetta Antonioli
, et al.
·
Journal of Personalized Medicine
·
7
PDF
Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports
2024
·
Irene Attucci
, Sofia Pilerci
, et al.
·
Cancer Reports
·
6
PDF
Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
2023
·
Elisabetta Antonioli
, Sofia Pilerci
, et al.
·
Frontiers in Oncology
·
5
Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial
2022
·
Sara Bringhen
, Mattia D'Agostino
, et al.
·
Blood
·
5
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
2021
·
Maria Livia Del Giudice
, Alessandro Gozzetti
, et al.
·
Medicina
·
5
PDF
Combined Minimal Residual Disease Evaluation in Bone Marrow and Apheresis Samples in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Improves Outcome Prediction
2025
·
Irene Attucci
, Benedetta Peruzzi
, et al.
·
Cancers
·
4
PDF
Ninety-Minute Daratumumab Infusions for Relapsed and Refractory Multiple Myeloma: Two Years of Italian Single-Center Observational Study
2021
·
Enrico Attardi
, Sofia Pilerci
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
3
B01 | Analysis of Sustained Minimal Residual Disease Negativity in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib-lenalidomide-dexamethasone With or Without Isatuximab (phase Iii Iskia Trial)
2025
·
F. Gay
, W. Roeloffzen
, et al.
·
Haematologica
·
2
P17 Clonal Plasma-cells in Stem Cell Apheresis as a Predictor of Progression in Newly Diagnosed Multiple Myeloma Patients Elegible for Autologous Stem Cell Transplantation
2023
·
S. Pilerci
, I. Attucci
, et al.
·
HemaSphere
·
2
MRD ‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥ VGPR / MRD ‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM
2026
·
Alessandro Gozzetti
, Paola Pacelli
, et al.
·
British Journal of Haematology
·
1
Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy
2025
·
Concetta Conticello
, Vittorio Del Fabro
, et al.
·
Annals of Hematology
·
1
PDF
PA-392 Real-World Efficacy and Safety of Daratumumab-Lenalidomide-Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Multicentre Italian Study
2026
·
Irene Attucci
, Elisabetta Antonioli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
PA-095 Clinical Implications of Discordant Frailty Assessment in Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Results from the Randomized Phase IV REAL MM Trial
2026
·
Lorenzo Cani
, Mattia D'Agostino
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P23 | Dara-vtd and Asct+ Lenalidomide Led to High Complete Reimission and Minimal Residual Disease Negativity Rates by Ngf: a Real-world Study of the Tuscan Myeloma Network in 228 Patients
2026
·
V. Venanzi
, S. Ciofini
, et al.
·
Haematologica
PDF
Pomalidomide, bortezomib and dexamethasone in multiple myeloma refractory to lenalidomide and anti-CD38 monoclonal antibodies: outcomes from a real-world experience
2026
·
Carmine Liberatore
, Virginia Valeria Ferretti
, et al.
·
Haematologica
PDF
Correction to: Continous or fixed carfilzomib, lenalidomide and dexamethasone (KRD) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life survey from European myeloma network (EMN) Italy
2025
·
Concetta Conticello
, Vittorio Del Fabro
, et al.
·
Annals of Hematology
PDF
The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study
2025
·
Gregorio Barila
, Francesco Tarantini
, et al.
·
Blood
PDF
Pomalidomide, Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Lenalidomide and Anti-CD38 Monoclonal Antibodies: A Multicentric Italian Retrospective Study
2024
·
Carmine Liberatore
, Paola Tacchetti
, et al.
·
Blood
PDF
P-171 Daratumumab As Consolidation Therapy in Multiple Myeloma Patients in >VGPR/MRD Positive After First Line Therapy: Final Analysis of the Multicentric Phase 2 Study DART4MM
2024
·
Alessandro Gozzetti
, Paola Pacelli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
P48 Carfilzomib, Lenalidomide and Dexamethasone in Relapsed Refractory Multiple Myeloma: a Prospective Real-life Experience of the Regional Tuscan Myeloma Network (rtm)
2023
·
I. Attucci
, E. Antonioli
, et al.
·
HemaSphere
P22 the Prognostic Role of 1q Abnormalities in Newly Diagnosed Multiple Myeloma Patients
2023
·
I. Attucci
, S. Pilerci
, et al.
·
HemaSphere
Case report: Unexpected parvovirus B19 infection in a myeloma patient treated with daratumumab
2022
·
Marianna Palazzo
, Gaia Ciolli
, et al.
·
Frontiers in Hematology
PDF
Show more works
View as search
Works count:
27
Citation count:
62
H-index:
5
I10-index:
1
Year
Topic
Type